Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death

被引：0
|
作者：
Javed, Faiza [1 ]
Mangino, Tony [1 ]
Piranavan, Paramarajan [1 ]
机构：
[1] Univ Kentucky, Coll Med, Lexington, KY USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0220
引用
收藏
页码：426 / 428
页数：3
相关论文
共 50 条
  • [1] Nirmatrelvir plus ritonavir in patients with underlying rheumatological diseases, in preventing COVID-19 related hospitalization and death
    Javed, Faiza
    Mangino, Anthony A.
    Piranavan, Paramarajan
    [J]. ADVANCES IN RHEUMATOLOGY, 2024, 64 (01):
  • [2] In patients with COVID-19 at risk for severe disease, nirmatrelvir plus ritonavir reduced hospitalization or death
    Vassilopoulos, Athanasios
    Mylonakis, Eleftherios
    [J]. ANNALS OF INTERNAL MEDICINE, 2022, 175 (06) : JC63 - JC63
  • [3] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    [J]. ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [4] Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
    Hashemian, Seyed Mohammad Reza
    Sheida, Amirhossein
    Taghizadieh, Mohammad
    Memar, Mohammad Yousef
    Hamblin, Michael R.
    Baghi, Hossein Bannazadeh
    Nahand, Javid Sadri
    Asemi, Zatollah
    Mirzaei, Hamed
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 162
  • [5] Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases
    Liu, Ting-Hui
    Wu, Jheng-Yan
    Huang, Po-Yu
    Hsu, Wan-Hsuan
    Chuang, Min-Hsiang
    Tsai, Ya-Wen
    Lai, Chih-Cheng
    Huang, Chun-Yen
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (1-3) : 121 - 128
  • [6] Paxlovid and COVID-19 related hospitalization or death in clinically extremely vulnerable patients
    Dormuth, Colin
    Kim, Jason D.
    Kuo, I. Fan
    Carney, Greg
    Fisher, Anat
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 265 - 265
  • [7] Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
    Reis, Stefanie
    Metzendorf, Maria-Inti
    Kuehn, Rebecca
    Popp, Maria
    Gagyor, Ildiko
    Kranke, Peter
    Meybohm, Patrick
    Skoetz, Nicole
    Weibel, Stephanie
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (09): : CD015395
  • [8] Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
    Hsu, Wan-Hsuan
    Tsai, Ya-Wen
    Wu, Jheng-Yan
    Liu, Ting-Hui
    Lai, Chih-Cheng
    [J]. JOURNAL OF INFECTION, 2023, 86 (04) : E107 - E110
  • [9] A case of tacrolimus intoxication due to the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid®)
    Westergerling, Parisa
    Kallenberger, Stefan
    Kaelble, Florian
    Dilger, Karin
    [J]. CLINICAL TOXICOLOGY, 2024, 62 : 69 - 70
  • [10] Practical guideline for Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir (Paxlovid) in COVID-19 Patients
    Goldstein, L.
    Zhurat, S.
    De Haan, T.
    Guy-Alfandary, S.
    Gueta, I
    Shihmanter, R.
    Golik, A.
    Eyal, S.
    Berkovitch, M.
    Berlin, M.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S54 - S55
12345